Thank you very much.
In fact, you both seem to agree with Dr. Berkley, CEO of Gavi, who answered a previous question by saying that the problem wasn't so much with patents and intellectual property, but with know‑how of the concentrates used to manufacture vaccines.
That being said, let me repeat my question, if only to keep this committee up to date, because there still seems to have been a compromise agreement between South Africa, the U.S., India and the E.U. Can you tell us where those negotiations stand today? If so, what would be the potential benefits of such an agreement?